PGC-1α

PGC-1α製品

All (4)
PGC-1α阻害剤 (1)
PGC-1α活性剤(3)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S1168	Valproic Acid sodium	Valproic Acid sodium is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.	Sci Total Environ, 2022, 838(Pt 2):155825 Acta Pharmacol Sin, 2022, 10.1038/s41401-022-00932-4 Transl Psychiatry, 2022, 12(1):130
S3944	VPA (Valproic acid)	VPA (Valproic acid) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.	Nat Commun, 2024, 15(1):668 Cell Mol Life Sci, 2024, 81(1):92 Cell Death Discov, 2024, 10(1):95
S7447	ZLN005	ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.	Front Immunol, 2023, 14:1089905 Anim Nutr, 2022, 11:121-131 Anim Nutr, 2022, 11:121-131
S8528	SR-18292	SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.	JCI Insight, 2023, 8(17)e170513 JCI Insight, 2023, 8(17)e170513 Anim Nutr, 2023, 10.1016/j.aninu.2023.07.001
S8528	SR-18292	SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.	JCI Insight, 2023, 8(17)e170513 JCI Insight, 2023, 8(17)e170513 Anim Nutr, 2023, 10.1016/j.aninu.2023.07.001
S1168	Valproic Acid sodium	Valproic Acid sodium is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.	Sci Total Environ, 2022, 838(Pt 2):155825 Acta Pharmacol Sin, 2022, 10.1038/s41401-022-00932-4 Transl Psychiatry, 2022, 12(1):130
S3944	VPA (Valproic acid)	VPA (Valproic acid) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.	Nat Commun, 2024, 15(1):668 Cell Mol Life Sci, 2024, 81(1):92 Cell Death Discov, 2024, 10(1):95
S7447	ZLN005	ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.	Front Immunol, 2023, 14:1089905 Anim Nutr, 2022, 11:121-131 Anim Nutr, 2022, 11:121-131

PGC-1α阻害剤の選択性比較